Rocket Lab's Order Book Is Booming Even as the Share Price Sits 59% Below Its Peak
Published on 09/12/2026 at 11:11 | Editorial boerse-global.de
Rocket Lab closed Friday at EUR 54.50, a gain of 2.1%, and on the surface that looks like small change. The context makes it more interesting: the advance came on a day stacked with positive announcements, yet the stock remains deep in negative territory over the past month. That gap between operational momentum and market performance is the central puzzle for anyone tracking the company right now.
A busy Friday, and a subdued reaction
The headline event was Rocket Lab's 95th Electron mission overall and its 16th of the year. Lifting off from Launch Complex 1 in New Zealand under the name "Happily Ever Faster," the rocket carried an Earth-observation satellite into a circular 500-kilometer orbit for an undisclosed customer. Shares had already added roughly 2% in pre-market trading before settling at the EUR 54.50 close.
The launch fits a dense operational rhythm. In early September, the company completed its 94th Electron mission, delivering a satellite for Japanese customer Synspective — part of a constellation for which another 16 missions are booked through 2030. The cadence makes clear that the small-launch core business is running smoothly despite the share-price slump.
Also on Friday, Raymond James analyst Brian Gesuale launched coverage with an Outperform rating and an $80 price target. His thesis rests on Rocket Lab's vertical integration, spanning launch vehicles, spacecraft and optical communications — a multi-legged business model that does not hinge on any single mission's success. That the stock responded only modestly suggests the market had already priced in much of the good news, or that broader concerns about risk and valuation are currently outweighing individual positive headlines.
The fundamentals keep pointing up
The operating picture offers little to worry about. Rocket Lab posted record second-quarter revenue of $234 million, up 62% year over year. Its backlog climbed to an all-time high of $2.36 billion, and management guided third-quarter revenue to between $250 million and $265 million.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The contract pipeline has broadened considerably. In August, the US Space Force awarded Rocket Lab a $397 million order under the SB-AMTI program, covering the development and operation of multiple flatellites on the upcoming Neutron rocket. Late in July, the company locked in its largest launch contract to date — a $266 million deal for up to 18 suborbital missions, to be flown largely from its new Kodiak, Alaska site. Satellite-build mandates from Viasat add to the mix.
Yet the stock trades 23% below its level of 30 days ago and 59% under its 52-week high of EUR 133.80. Bridging that disconnect between growth metrics and price action requires a credibility explanation — likely fed by the delay of Neutron's first flight, which analysts flag as the key execution risk.
Iridium: the second test
Beyond Neutron, the planned acquisition of Iridium Communications for roughly $8 billion in cash and stock remains a decisive factor. Iridium shareholders vote on the transaction on September 24, with closing targeted for mid-2027. The deal, announced in June, has already cleared antitrust review.
A transaction of that size reshapes Rocket Lab's risk profile. If the integration succeeds, the combined company gains a far broader satellite-infrastructure footprint; if it stumbles on regulatory or financial hurdles, it would weigh further on already fragile sentiment.
Institutional buyers versus a routine insider sale
While the stock shed about 23% over the past 30 days, large investors have been undeterred. Cathie Wood's ARK Investment Management bought roughly 681,000 Rocket Lab shares across two trading days ending September 9 — a clear vote of institutional conviction in the growth strategy for a company now valued at around EUR 36.44 billion.
CFO Adam C. Spice moved the other way, selling 140,157 shares on September 2 at a weighted average price of $62.63, a volume of about $8.8 million. The sale stemmed from the exercise of stock options at a strike price of $1.09 and was executed under an automated trading plan set up in June under Rule 10b5-1 — a pre-programmed transaction rather than a spontaneous insider exit.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
Wall Street sees room to run
Berenberg initiated coverage in early September with a Buy rating and an $83 price target, implying roughly 33% upside based on the then-prevailing price of $62.54. The analysts framed Rocket Lab as the only listed pure-play covering the entire space value chain — from launch through satellites to components and spectrum — with a de facto monopoly in the dedicated small-lift segment and an entry into medium-lift via Neutron.
One more structural piece is due to gain prominence toward year-end: the IMM Apex solar-cell technology, which boasts 31.5% efficiency and a 40% reduction in cell mass. The product eliminates germanium entirely, a design choice aimed at easing supply-chain risk across the space industry.
The technical picture
Momentum indicators confirm the stock is bruised. With an RSI of 37.8 and a gap of 22% below its 200-day moving average, Rocket Lab is in a clearly weakened technical posture. Over the long haul, the fundamental strength looks persuasive; in the near term, uncertainty around Neutron and the Iridium transaction is likely to keep price discovery difficult. For believers in the vertical-integration story, the current weakness may be a test of conviction — no all-clear, but no cause for panic either.
Ad
Rocket Lab Stock: New Analysis - 12 September
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
